https://charts.traderzeitung.de/phases/US45254E1073 string(1427) "{"isin":"US45254E1073","name":"Immuneering Corp","stock_id_xnas":22560584,"stock_id_xnys":null,"generated_at":"2026-09-24 01:32:00","days":[{"date":"2026-09-21","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":4.46,"close_at":"2026-09-21 21:59:00","complete":true,"perf_pct":null},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":4.4,"close_at":"2026-09-21 23:40:00","complete":true,"perf_pct":-1.3453}]},{"date":"2026-09-22","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":4.615,"close_at":"2026-09-22 21:59:00","complete":true,"perf_pct":4.8864},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":4.615,"close_at":"2026-09-22 22:00:00","complete":true,"perf_pct":0}]},{"date":"2026-09-23","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":4.39,"close_at":"2026-09-23 21:59:00","complete":true,"perf_pct":-4.8754},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":false,"perf_pct":null}]}]}"

Immuneering Aktie News & Nachrichten

[WKN: A3CWDN | Symbol: IMRX]

Realtimekurs

Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.

10J

Alles

Vorbörsliche Indikationen

Regulärer Handel

Nachbörslicher Handel

Artikel aus der Redaktion der Trader-Zeitung

Es konnten keine Nachrichten über Immuneering gefunden werden.

Immuneering Nachrichtenticker öffnen

MT Newswires 06.08.2026 13:20 Uhr

HC Wainwright nimmt Immuneering mit Buy und einem Kursziel von 14 US-Dollar auf

07:18 AM EDT, 08/06/2026 (MT Newswires) -- Immuneering (IMRX) hat laut von FactSet befragten Analysten ein durchschnittliches Rating von Buy und ein m

MT Newswires 15.06.2026 14:59 Uhr

Immuneering ernennt Andrew Gengos zum CFO

08:58 AM EDT, 06/15/2026 (MT Newswires) -- Immuneering (IMRX) hat Andrew Gengos zum Chief Financial Officer ernannt, mit Wirkung zum 16. Juli, teilte

MT Newswires 11.06.2026 14:25 Uhr

Immuneerings Phase-3-Studie von Atebimetinib plus mGnP zur Behandlung von Bauchspeicheldrüsenkrebs dosiert ersten Patienten

08:24 AM EDT, 06/11/2026 (MT Newswires) -- Immuneering (IMRX) teilte am Donnerstag mit, dass der erste Patient in einer Phase-3-Studie von Atebimetini